Your session is about to expire
← Back to Search
Patritumab Deruxtecan for Non-Small Cell Lung Cancer
Study Summary
This trial will test a new drug to treat lung cancer that has spread or returned after other treatments have been tried.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had enough time between my last treatment and the start of this trial.My cancer diagnosis includes small cell lung cancer, based on previous tissue tests.I have been treated with a platinum-based chemotherapy.My recent tests show my organs and bone marrow are working well.I am 18 years old or older.I haven't had any other cancer besides this one in the last 3 years.I am fully active or can carry out light work.I am taking more than 10 mg of prednisone or similar medication daily.I have active cancer spread to my brain or spinal cord.My cancer has worsened despite the latest treatment.I still have side effects from cancer treatment that haven't improved.My cancer has a specific EGFR mutation.I do not have cancer spread to the lining of my brain and spinal cord.I have or might have a lung condition like pulmonary fibrosis.I do not have major heart problems before starting the treatment.My lung cancer cannot be cured with surgery or radiation.You have HIV infection.You have an active hepatitis B or hepatitis C infection.I agree to provide the necessary tumor tissue for testing.I have severe breathing problems due to lung illness.I have been treated with HER3 antibody or topoisomerase I inhibitor.I have at least one tumor that can be measured for its size.
- Group 1: Study Group 1: Patritumab deruxtecan 5.6 mg/kg
- Group 2: Study Group 2: Patritumab deruxtecan Up-Titration
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Patritumab Deruxtecan (Up-Titration) for public use?
"Our experts at Power assigned a rating of 2 to the safety profile of Patritumab Deruxtecan (Up-Titration). This is based on its Phase 2 status, indicating that data exists in support of its security but not yet for efficacy."
What is the current sample size of this research project?
"In order to achieve the desired results, this study requires 420 people who meet its inclusion criteria. Potential participants may enroll at either University of Kansas in Kansas City or Ohio State University Comprehensive Cancer Center in Columbus."
Are there opportunities for enrolment in this experiment currently?
"Affirmative. Clinicaltrials.gov has verified that this research protocol, which was initially uploaded on February 2nd 2021, is actively searching for participants. 420 individuals are needed to be recruited from 6 different locations."
Share this study with friends
Copy Link
Messenger